



## **CRISPR Therapeutics to Participate in May Investor Conferences**

May 3, 2018

ZUG, Switzerland and CAMBRIDGE, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to present at two upcoming Investor Conferences.

### **Deutsche Bank's 43rd Annual Health Care Conference**

Date: Wednesday, May 9, 2018

Presentation: 10:40-11:15 AM ET

Location: Intercontinental Hotel, Boston, MA

### **Bank of America Merrill Lynch 2018 Health Care Conference**

Date: Thursday, May 17, 2018

Presentation: 8:40-9:10 AM PT

Location: Encore Hotel, Las Vegas, NV.

A live webcast of the presentations can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website at [www.crisprtx.com](http://www.crisprtx.com).

### **About CRISPR Therapeutics**

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. The Company has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit [www.crisprtx.com](http://www.crisprtx.com).

### **MEDIA CONTACT:**

Jennifer Paganelli

WCG on behalf of CRISPR

+1 347-658-8290 [jpaganelli@wgcworld.com](mailto:jpaganelli@wgcworld.com)

### **INVESTOR CONTACT:**

Chris Erdman

+1 617-307-7227 [chris.erdman@crisprtx.com](mailto:chris.erdman@crisprtx.com)

Chris Brinzey

Westwicke Partners for CRISPR

+1 339-970-2843 [chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)



Source: CRISPR Therapeutics AG